Small cell lung cancer, which occurs almost exclusively in smokers, is a malignancy characterised by rapid doubling time, high growth fraction and widespread metastasis at presentation. In this presentation, we will briefly discuss the classification of pulmonary Neuro-endocrine tumours by the World Health Organisation followed by a detailed discussion of the clinical features, lab evaluation and management of SCLC, both limited and extended stage. The frontline therapy in small cell lung cancer is etoposide and cisplatin along with thoracic radiotherapy and prophylactic cranial irradiation in patients who have a good response to therapy. Hyperfractionation of radiotherapy may provide some benefit but is also associated with increase incidence of complications. Newer agents for SCLC include Vandetanib and immunotherapy molecules, such as Iplimumab and nivolumab.

Check out our other videos

Ascites
https://www.youtube.com/watch?v=Uvl8UCwSUI4

Aplastic anemia
https://www.youtube.com/watch?v=OlAMqP-El8c

Acute kidney injury
https://www.youtube.com/watch?v=73QwSB6JuNA

Cardio renal syndrome
https://youtu.be/6KKDpAVkBK4

Vasculitis: Causes, clinical features and management
https://youtu.be/lCLK7RWlJts

Dengue fever: clinical features and management
https://youtu.be/VNQV8KgT3-Q

Addison’s disease
https://youtu.be/JVKycyaSvIk

Hepatopulmonary syndrome
https://youtu.be/uu50uWjR-rg

Osteoporosis
https://youtu.be/RP5OOb5zQd4

Hypertensive emergencies
https://youtu.be/kmNcV4Zxljo

Hepatorenal syndrome
https://youtu.be/QvP0AcoWjuw

Approach to a case of Anemia
https://youtu.be/ElL-yYKHgW0

Meningitis and Encephalitis
https://youtu.be/6rE19sE6GR8

We would like to thank the following resources:

Royalty free stock images from
www.pexels.com

Professional powerpoint templates by
Creative Venus Youtube channel

Initial smoke stock royalty free footage from
www.videezy.com

Join Dr. Mohid Khan as he unravels the complexities of neuroendocrine tumours (NETs). This in-depth conversation aims to inform and guide patients, caregivers, and healthcare professionals alike. Gain insights into the latest developments in NET diagnosis, understand the signs and symptoms to watch out for, and learn about the best practices in treatment and care management.

Find our CPD course here 👉 https://bit.ly/3MMjIhd

#NeuroendocrineTumours #MedicalEducation #OnlineLearning #StudyPRN

This episode of NETRF’s NETWise podcast discusses Peptide Receptor Radionuclide Therapy (PRRT) a targeted form of radiotherapy approved in the U.S. in 2018. Listen in as NET experts like Josh Mailman, Drs. George Fisher, Thor Halfdanarson, Ed Wolin, Richard Baum, and others explain what it is, how it works, and who is most likely to benefit from PRRT. This therapy relies on a tumor’s expression of somatostatin receptors. We explain what they are and how to know if you have them.

Then, we’ll take an objective look at the success rates for this therapy. What does research, like the NETTER-1 study, tell us about outcomes for this form of treatment? To give you information about both the pros and cons of PRRT, we will also discuss the potential side effects, from mild to serious. To give you a sense of what it is like to undergo PRRT, we’ll talk with multiple patients about their experience with the procedure itself, as well as the radiation safety precautions patients should take immediately following treatment. Finally, we look to the future asking Drs. Rod Hicks and Tom Hope to explain some of the new therapeutic directions PRRT is taking.

HANDOUTS
- This handout explains how radioactive drugs are able to target NET cells with radioactivity using PRRT. https://netrf.org/wp-content/u....ploads/2020/03/NetWi

- This handout is a quick guide to answer your most basic questions about the pros and cons of PRRT. What are the benefits of PRRT? What are the potential side effects of PRRT? Who can be treated with PRRT? https://netrf.org/wp-content/u....ploads/2020/03/NetWi

- Download a transcript https://netrf.org/wp-content/u....ploads/2020/03/NETWi

Email questions or feedback to podcast@netrf.org.

(c) 2020 NETRF
______________________________________________________

This episode was made possible by the generous support of Ipsen Biopharmaceuticals, the Vincent E. Taylor Patient Education Fund, Advanced Accelerator Applications, a Novartis Company, and Lexicon Pharmaceuticals.

NETRF.org is a leading funder of neuroendocrine tumor research in the U.S. and abroad. As a nonprofit foundation, NETRF is also committed to educating patients and families about #NeuroendocrineCancer with:

- Live patient conferences and YouTube live streams https://netrf.org/events/patie....nt-and-caregiver-con
- Web-based information https://netrf.org/for-patients/nets-info/
- NETWise podcast https://netrf.org/podcast/
- Free printed guide to neuroendocrine cancer for patients and families

Get #NeuroendocrineTumor news and info
-Subscribe to NETRF newsletter https://signup.e2ma.net/signup/1815153/1773232/
-Facebook https://www.facebook.com/NETRF/
-Twitter https://twitter.com/CureNETs

FAQs on Lung cancer കൂടുതല്‍ വിവരങ്ങള്‍ക്ക് www.keralacancercare.com
സന്ദർശിക്കുക